2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Radionuclide-Drug Conjugates (RDCs)

Radionuclide-Drug Conjugates (RDCs)

Radionuclide-drug conjugates (RDCs) are one of the most promising development directions for nuclear drug targeted therapy. RDC is composed of targeting element, linker, chelate and radioactive isotope. RDC has advantages in early tumor diagnosis, treatment and postoperative tumor evaluation. The same ligand can be connected to nuclides used for disease diagnosis and treatment respectively, promoting the integration of diagnosis and treatment of RDC drugs.

Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products:

Radionuclide-Drug Conjugates (RDCs) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-157977
    DOTA-GA-maleimide
    		99.26%
    DOTA-GA-maleimide is a macrocyclic chelator, which forms stable complex with metals. DOTA-GA-maleimide is utilized as radiolabelled imaging agent.
    DOTA-GA-maleimide
  • HY-134418
    NOTA
    		≥98.0%
    NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools. NOTA also can be used for probe design and signal amplification via the multivalent effect.
    NOTA
  • HY-P10131
    3BP-3940
    		99.96%
    3BP-3940 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-3940 is often coupled with radionuclides for tumor diagnosis and treatment.
    3BP-3940
  • HY-100138
    2-Aminoethyl-mono-amide-DOTA-tris(tBu ester)
    		≥98.0%
    2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) is a macrocycle DOTA derivative for tumor pretargeting.
    2-Aminoethyl-mono-amide-DOTA-tris(tBu ester)
  • HY-155483
    PSMA-BCH
    		99.93%
    PSMA-BCH (NOTA-PSMA) is a NOTA-conjugated precursor. NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools.
    PSMA-BCH
  • HY-132989
    Mal-Deferoxamine
    Mal-Deferoxamine is a maleamide (Mal)-containing Deferoxamine (HY-B1625). Mal selectively covalently binds to sulfur groups to produce a linking reaction. Mal-Deferoxamine can be combined with radionuclides to synthesize radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy..
    Mal-Deferoxamine
  • HY-P99326
    Tositumomab
    Tositumomab is a murine IgG2a lambda monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes.
    Tositumomab
  • HY-W717743
    DOTAM-mono-acid
    		≥98.0%
    DOTAM-mono-acidis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-mono-acid can be used for conjugation of peptides and radionuclides.
    DOTAM-mono-acid
  • HY-W614269
    DOTA-GA(tBu)4
    		≥98.0%
    DOTA-GA(tBu)4 is a macrocyclic chelator used in medical imaging.
    DOTA-GA(tBu)4
  • HY-W782083
    p-SCN-Bn-NOTA trihydrochloride
    		99.62%
    p-SCN-Bn-NOTA (trihydrochloride)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. p-SCN-Bn-NOTA (trihydrochloride) can be used for conjugation of peptides and radionuclides.
    p-SCN-Bn-NOTA trihydrochloride
  • HY-160607
    MMA-NODAGA
    MMA-NODAGA is a chelator for site-specific labeling of targeting proteins containing unpaired cysteine. MMA-NODAGA can be used to conjugate with exosome and 64Cu in image with positron emission tomography (PET)<[2].
    MMA-NODAGA
  • HY-D2363
    DOTA.SA.FAPi TFA
    		99.26%
    DOTA.SA.FAPi TFA is a bifunctional DATA5m and DOTA chelator, which is composed of the squaric acid and UAMC1110. DOTA.SA.FAPi TFA inhibits fibroblast activation protein (FAP) with an IC50 of 0.9 nM. DOTA.SA.FAPi TFA targets protease PREP with an IC50 of 5.4 μM. DOTA.SA.FAPi TFA can be used a PET tracer, when labeled with 68Ga, and used for research about cancer.
    DOTA.SA.FAPi TFA
  • HY-W782078
    Butyne-DOTA
    Butyne-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Butyne-DOTA can be used for conjugation of peptides and radionuclides.
    Butyne-DOTA
  • HY-111605
    Macropa-NCS
    Macropa-NCS can be coupled with antibodies to form tumor-selective carrier molecules, which can be further combined with radionuclides as specific targeting cancer cell carriers, and is a linker-chelating agent in targeted alpha research (TAT).
    Macropa-NCS
  • HY-W749627
    NO2A-Butyne
    		≥98.0%
    NO2A-Butyneis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Butyne can be used for conjugation of peptides and radionuclides.
    NO2A-Butyne
  • HY-W087187
    DOTAGA-anhydride
    DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride can be used to label monoclonal antibodies (mAbs) such as trastuzumab (targeting HER2/neu receptor with an affinity of 5.5 nM) under mild conditions (PBS pH 7.4, 25 °C, 30 minutes) after chelation with indium-111. [111In-DOTAGA]-trastuzumab showed a tumor uptake of 65% ID/g in mice bearing breast cancer BT-474 xenografts 72 hours after injection, which is valuable for SPECT/CT imaging and biodistribution studies.
    DOTAGA-anhydride
  • HY-138134
    NOTP
    NOTPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTP can be used for conjugation of peptides and radionuclides.
    NOTP
  • HY-158266
    DOTA-PSMA-EB-01
    DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC50= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of 177Lu in tumors.
    DOTA-PSMA-EB-01
  • HY-W539916
    Azido-mono-amide-DOTA
    Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.
    Azido-mono-amide-DOTA
  • HY-P5520
    GB-6
    GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects.
    GB-6
Radionuclide-Drug Conjugates (RDCs) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.